SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001628280-22-014413
Filing Date
2022-05-16
Accepted
2022-05-16 08:08:35
Documents
13
Period of Report
2022-05-12
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K nltx-20220512.htm   iXBRL 8-K 41345
  Complete submission text file 0001628280-22-014413.txt   204519

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT nltx-20220512.xsd EX-101.SCH 2150
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE DOCUMENT nltx-20220512_def.xml EX-101.DEF 14568
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT nltx-20220512_lab.xml EX-101.LAB 27958
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT nltx-20220512_pre.xml EX-101.PRE 15117
7 EXTRACTED XBRL INSTANCE DOCUMENT nltx-20220512_htm.xml XML 10665
Mailing Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102
Business Address SUITE 360 - 1616 EASTLAKE AVE EAST SEATTLE WA 98102 206-732-2133
Neoleukin Therapeutics, Inc. (Filer) CIK: 0001404644 (see all company filings)

IRS No.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36327 | Film No.: 22925624
SIC: 2834 Pharmaceutical Preparations